Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
复制标题
DOI：
10.1016/s1470-2045(22)00139-5
复制
发表时间：
2022-08
期刊：
影响因子：
51.1
通讯作者：
Bookman, Michael A.
中科院分区：
文献类型：
--
作者：
Vergote, Ignace;Gonzalez-Martin, Antonio;Lorusso, Domenica;Gourley, Charlie;Mirza, Mansoor Raza;Kurtz, Jean-Emmanuel;Okamoto, Aikou;Moore, Kathleen;Kridelka, Frederic;McNeish, Iain;Reuss, Alexander;Votan, Benedicte;du Bois, Andreas;Mahner, Sven;Ray-Coquard, Isabelle;Kohn, Elise C.;Berek, Jonathan S.;Tan, David S. P.;Colombo, Nicoletta;Zang, Rongyu;Concin, Nicole;O'Donnell, Dearbhaile;Rauh-Hain, Alejandro;Herrington, C. Simon;Marth, Christian;Poveda, Andres;Fujiwara, Keiichi;Stuart, Gavin C. E.;Oza, Amit M.;Bookman, Michael A.
妇科癌症组(GCIG)第六届卵巢癌临床研究会议(OCCC6)实际上是在2021年10月根据公布的共识指南举行的。协商一致会议的目标是在即将进行的试验的设计要素上实现统一，为今后的研究挑选重要问题，并查明未得到满足的需求。GCIG所有33个成员小组都参与了4个主题小组关于临床研究(包括一线治疗、复发性疾病、疾病亚组和未来试验)的20项声明的制定、完善和通过。20个陈述中有14个获得了一致的共识，其余6个陈述的符合率为90%。GCIG各小组积极审议后的高接受率证实，可以在虚拟环境中采用协商一致的进程。连同对未满足需求的详细分类，这些共识声明将促进卵巢癌国际临床研究的协调。
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research (OCCC6) was held virtually in October 2021 following published consensus guidelines. The goal of the consensus meeting was to achieve harmonization on design elements of upcoming trials, to select important questions for future study and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within 4 topic groups on clinical research including first line treatment, recurrent disease, disease subgroups and future trials. Unanimous consensus was obtained for 14 of 20 statements, with >90% concordance in the remaining 6 statements. The high acceptance rate following active deliberation amongst the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote harmonisation of international clinical research in ovarian cancer.